See article, p. 568.

Hematologic malignancy patients are highly susceptible to severe coronavirus disease-19 (COVID-19) illness and are a high-priority group for vaccination to mitigate COVID-19–related morbidity and mortality. Chung et al. find differential COVID-19 vaccine humoral responses between hematologic malignancy subtypes and disease-specific therapies across patient cohorts. Hematologic malignancy patients undergoing active therapy have baseline humoral responses that are further suppressed. Importantly, antibody titers alone are an imperfect measure of immunity, as many patients with positive anti–SARS-CoV-2 antibody titers have insufficient neutralizing capacity. These findings together provide important metrics for optimizing the clinical care of this vulnerable population.

See article, p. 577.

Cellular therapies, including allogeneic and autologous hematopoietic cell transplant (allo-HCT, auto-HCT) and chimeric antigen receptor T-cell therapy (CAR T), render patients severely immunocompromised for extended periods after therapy. Tamari et al. define predictors of response to COVID-19 vaccine to nominate important factors for optimizing response...

You do not currently have access to this content.